Eryseng Parvo
Active substance
ATC code
Species
Pigs
Indications
For the active immunisation of female pigs for the protection of progeny against transplacental infection caused by porcine parvovirus.
For the active immunisation of male and female pigs to reduce clinical signs (skin lesions and fever) of swine erysipelas caused by Erysipelothrix rhusiopathiae, serotype 1 and serotype 2.
Onset of immunity:
Porcine parvovirus: from the beginning of the gestation period.
E. rhusiopathiae: three weeks after completion of the basic vaccination scheme.
Duration of immunity:
Porcine parvovirus: vaccination provides foetal protection for the duration of gestation. Revaccination should be performed prior to each gestation, see section 4.9.
E. rhusiopathiae: vaccination protects against swine erysipelas until the time of the recommended revaccination (approximately six months after the basic vaccination scheme), see section 4.9.
Dose to be administered and administration route
Administer one dose of 2 ml by intramuscular injection in the neck muscles according to the following schedule:
Basic vaccination:
Pigs from 6 months of age which have not been previously vaccinated with the product should be given two injections with an interval of 3–4 weeks. The second injection should be administered 3–4 weeks before mating.
Revaccination:
A single injection should be given 2–3 weeks prior to each subsequent mating (approximately every 6 months).
For simultaneous use with UNISTRAIN PRRS in sows for reproduction from 6 months of age, the mixed administration of ERYSENG PARVO and UNISTRAIN PRRS should only be used when vaccinating animals prior to mating.
The following instructions should be used: the contents of a single vial of UNISTRAIN PRRS should be reconstituted with the contents of a single vial of ERYSENG PARVO. A single dose (2 ml) of the mixed vaccines should be injected within a period of 2 hours via intramuscular use.
UNISTRAIN PRRS ERYSENG PARVO
10 doses + 10 doses (20 ml)
25 doses + 25 doses (50 ml)
50 doses + 50 doses (100 ml)
Allow the vaccine to reach room temperature (15–25 ºC) before administration. Shake well before use.
